Articles tagged "Heart transplant patients"

2016 American Transplant Congress
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).
M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
¹European Georges Pompidou Hospital, Paris, France; ²La Pitié Salpêtrière Hospital, Paris, France; ³Saint-Louis Hospital, Paris, France; ⁴Necker Hospital, Paris, France.
Introduction The role of circulating DSA in addition to traditional cardiovascular risk factors, in the development of accelerated CAV have not been demonstrated. We investigated…
2016 American Transplant Congress
Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.
P. Jindra,¹ S. Nicholas,² J. Chappelle,¹ T. Humlicek,² K. Hosek,² J. Heinle,² S. Denfield,² A. Jeewa,² R. Kerman,¹ W. Dreyer.²
¹Surgery Immune Evaluation Lab, Baylor College of Medicine, Houston, TX; ²Pediatrics, Baylor College of Medicine, Houston, TX.
Purpose: Utilization of positive (+) cross-match (XM) hearts is tempting when shortages of pediatric donor hearts exist, especially for patients with high pre-transplant panel reactive…
2016 American Transplant Congress
The Quilty Effect in Pediatric Heart Transplant Recipients.
A. Joong,¹ M. Richmond,¹ K. Stack,² R. Rodriguez,¹ J. McAllister,² W. Zuckerman,¹ T. Lee,¹ S. Law,¹ L. Addonizio.¹
¹Pediatric Cardiology, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.
Purpose: The Quilty effect is defined as the presence of a nodular endocardial infiltrate of lymphocytes in an endomyocardial biopsy (EMB), and has been described…
2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
M. Bakir, N. Jackson, E. Chang, D. Henriquez-Ticas, C.-H. Tseng, T. Khuu, J. Zhang, E. Reed, M. Deng, M. Cadeiras.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…
2016 American Transplant Congress
Solid Phase Assay Demonstrates High Rates of Allosensitization in Pediatric Heart Recipients.
W. Zuckerman,¹ B. Feingold,² A. Zeevi,² C. Bentlejewski,² L. Addonizio,¹ E. Blume,³ C. Canter,⁴ A. Dipchand,⁵ D. Hsu,⁶ R. Shaddy,⁷ W. Mahle,⁸ K. Much,⁹ B. Armstrong,⁹ D. Ikle,⁹ H. Diop,¹⁰ J. Odim,¹⁰ S. Webber.¹¹
¹Columbia Univ., NYC; ²Univ. of Pittsburgh, Pittsburgh; ³Boston Children's Hospital, Boston; ⁴Washington Univ., St. Louis; ⁵Sick Kids, Toronto, Canada; ⁶Children's Hospital, Montefiore, NYC; ⁷Children's Hospital of Philadelphia, Philadelphia; ⁸CHOA, Atlanta; ⁹Rho, Chapel Hill; ¹⁰NIAID/NIH, Bethesda; ¹¹Vanderbilt Univ., Nashville.
Allosensitization is a risk factor for rejection, vasculopathy and graft loss. CTOTC-04 is a prospective study assessing the impact of sensitization on a composite of…
2016 American Transplant Congress
Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.
A. Vu,¹ A. Althouse,² A. Zeevi,³ J. Teuteberg,² M. Shullo.²
¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Pathology Department, University of Pittsburgh, Pittsburgh, PA.
Purpose: Cardiac allograft vasculopathy (CAV) is a significant complication after cardiac transplantation (CTX). The presence of donor specific antibodies (DSA) has been associated with an…
2016 American Transplant Congress
A Risk Quantification Score for Heart Transplants: A Heart Donor Risk Index.
A. Israni,^1,2 D. Zaun,¹ J. Snyder,¹ N. Salkowski,¹ H. Xiong,¹ B. Kasiske,^1,2 M. Colvin,^1,3 M. Colvin.^1,3
¹Scientific Registry of Transplant Recipients, Minneapolis; ²Hennepin County Medical Center, Univ of MN, Minneapolis; ³Univ of Michigan, Ann Arbor.
Background: To better risk stratify heart transplants, we developed a continuous heart donor risk index (HDRI) based on heart donors to quantify heart allograft failure.Methods:…
2015 American Transplant Congress
Elevated ST2 Levels Are Associated With Increased Risk of Antibody Mediated Rejection in Heart Transplant Recipients
A. Grupper,¹ S. Kushwaha,¹ O. Abou Ezzeddine,¹ J. Geske,² W. Kremers,² B. Edwards,¹ N. Pereira.¹
¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Objective: Serum ST2, a member of the interleukin (IL) 1 receptor family, is a novel biomarker that reflects cardiac remodeling and fibrosis and is associated…
2015 American Transplant Congress
Longitudinal Multi-Omic Profiling of Genes and Pathways Underlying Cardiac Allograft Rejection
B. Piening,¹ Y. Li,² A. Shaked,² B. Keating,² M. Snyder.¹
¹Genetics, Stanford University School of Medicine, Stanford, CA; ²University of Pennsylvania, Philadelphia, PA.
Our ability to treat cardiac allograft rejection in both acute and chronic states is typically limited by poor existing biomarkers to predict the occurrence of…
2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
L. Donohue, W. Ally, S. Dunn, J. Kennedy, J. Bergin.
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…